This Supplier Spotlight® highlights BPS Bioscience, a biotechnology development and manufacturing company focused on innovating proteins, antibodies, cell lines, lentiviruses and assay kits for biopharmaceutical and academic research.
What is your company’s mission?
BPS Bioscience’s purpose is to advance new scientific discoveries by creating innovative solutions for research that lead to therapies. Breakthroughs in research rely on dependable model systems that accurately reflect biological systems. We are experts in protein design, expression, purification and characterization; cell line and lentivirus engineering; and biochemical and cellular assay development. Our products and services have enabled thousands of researchers to advance biological discoveries across a wide variety of disciplines, including epigenetics, cell signaling, SARS-CoV-2, immunotherapy, adoptive cell therapies and many more.
Science never stands still. We focus on emerging research needs and rapidly deliver solutions. Every month, we consistently launch new products, many of which are novel to the research market. We are driven by our core values of encouraging innovation and creativity, providing exceptional customer service, prioritizing teamwork, embracing diversity, learning, working with integrity and delivering excellence.
What products and services do you offer?
The core products that we develop are recombinant proteins, antibodies, assay kits, recombinant cell lines and lentiviruses. We provide over 4,000 products mainly focused on immunotherapy, epigenetics, coronaviruses, CRISPR, cell signaling and cell metabolism. BPS Bioscience can supply products in large-scale bulk quantities, as well as through contract and custom manufacturing. Our scientific expertise has enabled specific research projects by delivering custom cell lines and cell-based assays, lentiviruses, proteins and biochemical assays. The company also provides biochemical and cell-based screening services using our 200+ in-house developed assay systems.
What problems do you solve?
BPS Bioscience started by developing hard-to-make recombinant proteins and protein complexes related to epigenetics and cell signaling that were not readily available commercially. The biofunctional proteins were then applied to the development of biochemical assay kits, which are now provided in over seven different formats, including chemiluminescence, UV/vis and colorimetric, fluorogenic, TR-FRET, fluorescence polarization and AlphaLISA®. More recently, the company has expanded its expertise to recombinant cell line and lentivirus tools, further enabling cell-based research. Many of our research tools are novel and not available from other manufacturers. As the COVID-19 pandemic began to escalate in early 2020, BPS Bioscience was one of the first companies to provide recombinant proteins, assay kits, recombinant cell lines and pseudotyped lentiviruses for critical research in drug and vaccine development against SARS-CoV-2. We continue to develop new reagents against emerging SARS-CoV-2 variants, including Omicron and its subvariants.
What are the most innovative tools and technologies that you offer?
We provide a large selection of novel, innovative tools across our portfolio of products. We’ve recently released Omicron-specific assay kits for the study of the newest variant of SARS-CoV-2, one of which is an Omicron variant 3CL Protease assay that measures the viral protease activity. This homogeneous assay is well-suited for high-throughput compound screening for potential protease inhibitors. We also offer a large selection of KRAS mutant proteins for both isoform A and B that are pre-loaded with GDP for use in nucleotide exchange assays, which are well suited for screening and profiling of mutation-specific KRAS antagonists/inhibitors. Lastly, we innovated a PARPtrap™ Combo Assay for PARP1 and PARP2 that allows researchers to distinguish selective inhibitors for either PARP1 or PARP2.
We are also present in the immuno-oncology space, with tools to optimize and characterize CAR T cells, reagents to help develop checkpoint regulator drugs and cell lines ready to use in co-culture functional assays.
We manufacture over 100 unique proteins, assays, cell lines and lentiviruses that are not available elsewhere, and we will continue to push these innovations as new research demands emerge.
What are your competitive advantages?
BPS Bioscience is a small yet nimble company that can quickly deliver new, urgently needed products to market. We are adept at anticipating the future directions of research areas for drug development and are not afraid to take risks in creating research tools for emerging topics. We are committed to being research partners and have developed a significant number of custom products for our clients. Among the over 100 unique products that we offer, these include novel protein and enzyme complexes, reporter cell lines, overexpressing cell lines, pseudotyped lentiviruses, biochemical assay kits in multiple formats, CRISPR/Cas9 protein-specific lentiviruses and much more. With our novel assay kits, we can also provide screening services that would not be available elsewhere.
Who are your clients?
We work with big and small pharma and biotechnology companies, vaccine developers, AI-based therapy companies, research institutes and academic university labs.
What new products and services are you developing in 2022?
As new SARS-CoV-2 variants emerge, we will be ready to rapidly deliver variant-specific research tools. We will also be driving forward with new products for epigenetics, immunotherapy and cell signaling research. When assay kits become available, we will also offer them as services available for screening and profiling of compounds.
Where are your laboratories and offices located?
Our headquarters and laboratories are based in San Diego, CA. We have distributors worldwide to support researchers across the globe.
Connect with BPS Bioscience.